Comparative Pharmacology
Head-to-head clinical analysis: TECHNESCAN MAG3 versus TECHNETIUM TC 99M MEBROFENIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TECHNESCAN MAG3 versus TECHNETIUM TC 99M MEBROFENIN.
TECHNESCAN MAG3 vs TECHNETIUM TC-99M MEBROFENIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TECHNESCAN MAG3 (mertiatide) is a radiopharmaceutical that undergoes renal tubular secretion via the organic anion transporter (OAT) system, allowing dynamic imaging of renal perfusion and function. After intravenous administration, it exhibits rapid clearance from the blood by the kidneys, providing assessment of effective renal plasma flow.
Technetium Tc-99m mebrofenin is a radiopharmaceutical that, after intravenous administration, is taken up by hepatocytes and excreted into the biliary system. It allows scintigraphic imaging of the liver and biliary tract by emitting gamma rays detectable by a gamma camera.
185-370 MBq (5-10 mCi) intravenous bolus injection for renal imaging.
Adults: 1-5 mCi (37-185 MBq) IV bolus. Image immediately and at intervals up to 60 minutes for hepatobiliary scintigraphy.
None Documented
None Documented
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Teriflunomide
"The serum concentration of Teriflunomide can be increased when it is combined with Technetium Tc-99m mebrofenin."
Clinical Note
moderateTechnetium Tc-99m mebrofenin + Eltrombopag
"The serum concentration of Eltrombopag can be increased when it is combined with Technetium Tc-99m mebrofenin."
Terminal elimination half-life: approximately 2.5 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life: approximately 6 hours (range 4-8 hours) in patients with normal hepatic function. In obstructive jaundice, half-life may be prolonged due to delayed biliary excretion.
Renal: approximately 90% of injected dose excreted by glomerular filtration and tubular secretion within 24 hours; biliary/fecal: <1%.
Primarily biliary (hepatobiliary) excretion: ~75% of administered activity is excreted into bile and subsequently into feces within 24 hours. Renal excretion accounts for <10% of the administered dose.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical